Bookedited by Edward P. Gelmann, chief,
... Show More Division of Hematology/Oncology and deputy director for Clinical Research, Herbert Irving Comprehensive Cancer Center and Columbia University Medical Center, New York, NY, USA, Charles L. Sawyers, chair, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Frank J. Rauscher III, professor, Gene Expression and Regulation Program, professor, Tumor Microenvironment and Metastasis Program, deputy director for Basic Research, Wistar Institute Cancer Center, Philadelphia, PA, USA.
Summary: "The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target"-- Provided by publisher. "This book was conceived more than five years before its publication date. It was intended to provide a resource that summarized technology, biochemistry, molecular pathophysiology, and targeted therapeutics. As contributors were being recruited and chapters written the field that was being described changed at an accelerating pace. It is a tribute to scientific progress that volumes like this one are out-of-date as they are published, but books like this are not meant to contain the most current laboratory discovery or report the most recent FDA approval"-- Provided by publisher.
Contents:
Part 1.1. Analytical techniques: analysis of DNA
Part 1.2. Analytical techniques: analysis of RNA
Part 2.1. Molecular pathways underlying carcinogenesis: signal transduction
Part 2.2. Molecular pathways underlying carcinogenesis: apoptosis
Part 2.3. Molecular pathways underlying carcinogenesis: nuclear receptors
Part 2.4. Molecular pathways underlying carcinogenesis: DNA repair
Part 2.5. Molecular pathways underlying carcinogenesis: cell cycle
Part 2.6. Molecular pathways underlying carcinogenesis: other pathways
Part 3.1. Molecular pathology: carcinomas
Part 3.2. Molecular pathology: cancers of the nervous system
Part 3.3. Molecular pathology: cancers of the skin
Part 3.14 Molecular pathology: endocrine cancers
Part 3.5. Molecular pathology: adult sarcomas
Part 3.6. Molecular pathology:lymphoma and leukemia
Part 3.7. Molecular pathology: pediatric solid tumors
Part 4. Pharmacologic targeting of oncogenic pathways.